Company Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Telix Pharmaceuticals Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 01:26:27 03/05/2024 BST			5-day change	1st Jan Change
14.89 ^AUD	+0.61%		+4.06%	+47.62%

01:51am	Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP	MT
04-30	Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	MT

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).

Number of employees: 234

AUD in Million	2022	Weight	2023	Weight	Delta
Commercial 98.9 %	156	97.7 %	497	98.9 %	+217.87%
Product Development 1.1 %	4	2.3 %	5	1.1 %	+47.46%

AUD in Million	2022	Weight	2023	Weight	Delta
United States 97.4 %	150	93.7 %	490	97.4 %	+226.42%
China 1.1 %	3	2.1 %	5	1.1 %	+57.80%
Other Countries 0.9 %	2	1.6 %	5	0.9 %	+87.06%
United Kingdom 0.3 %	2	1.3 %	1	0.3 %	-36.14%
Australia 0.2 %	0	0.1 %	1	0.2 %	+682.55%
Belgium 0.1 %	1	0.4 %	0	0.1 %	-18.79%

Managers	Title	Age	Since
Andreas Kluge FOU	Founder	-	31/10/15
Christian Behrenbruch FOU	Founder	-	31/10/15
Darren Smith DFI	Director of Finance/CFO	58	31/01/22
Craig Ulrick CTO	Chief Tech/Sci/R&D Officer	-	-
Tracey Brown CTO	Chief Tech/Sci/R&D Officer	61	31/01/20
Michael Wheatcroft CTO	Chief Tech/Sci/R&D Officer	-	-
Melanie Farris CMP	Compliance Officer	-	-
David Cade CTO	Chief Tech/Sci/R&D Officer	-	06/10/19
Kyahn Williamson IRC	Investor Relations Contact	-	11/07/21
Meredith Crowe HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Harry McCann CHM	Chairman	83	16/09/17
Christian Behrenbruch FOU	Founder	-	31/10/15
Mark Nelson BRD	Director/Board Member	-	16/09/17
Tiffany Olson BRD	Director/Board Member	64	30/03/22
Jann Skinner BRD	Director/Board Member	66	18/06/18
Andreas Kluge FOU	Founder	-	31/10/15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	323,727,000	247,357,796 ( 76.41 %)	0	76.41 %

Name	Equities	%	Valuation
Andreas Kluge 6.999 %	22,675,000	6.999 %	191 M $
Christian Behrenbruch 6.999 %	22,675,000	6.999 %	191 M $
GRAND PHARMACEUTICAL GROUP LIMITED 3.379 %	10,947,181	3.379 %	92 M $
UV-Cap Verwaltungs GmbH 2.301 %	7,454,500	2.301 %	63 M $
Oncidium Foundation 1.830 %	5,929,331	1.830 %	50 M $
TELIX PHARMACEUTICALS LIMITED 1.018 %	3,298,073	1.018 %	28 M $
Mark Nelson 0.9966 %	3,228,750	0.9966 %	27 M $
Yelwac Pty Ltd. 0.6117 %	1,981,804	0.6117 %	17 M $
Netwealth Investments Ltd. 0.5998 %	1,943,357	0.5998 %	16 M $
Aglub Investments Pty Ltd. 0.5350 %	1,733,342	0.5350 %	15 M $

Name	Equities	%	Valuation
TELIX PHARMACEUTICALS LIMITED 1.02%	3,298,073	1.02%	27,734,947 $

Telix Pharmaceuticals Ltd.

55 Flemington Road Suite 401

3051, Melbourne

http://www.telixpharma.com

address Telix Pharmaceuticals Limited(TLX)

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.8 AUD

Average target price

15.29 AUD

Spread / Average Target

+3.30%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TELIX PHARMACEUTICALS LIMITED	+47.62%	3.15B
MODERNA, INC.	+26.28%	42.68B
IQVIA HOLDINGS INC.	-3.99%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B
BIO-TECHNE CORPORATION	-2.02%	11.55B

Other Biotechnology & Medical Research